Covered recipient · General Payments record
HOWARD J RUBENSTEIN
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$1,250.93
61 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,250.93 | 61 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $186.08 | 12 |
| Novo Nordisk Inc | $151.74 | 7 |
| Esperion Therapeutics, Inc. | $139.89 | 2 |
| AstraZeneca Pharmaceuticals LP | $136.23 | 2 |
| PFIZER INC. | $136.00 | 9 |
| Merck Sharp & Dohme Corporation | $97.76 | 6 |
| Amarin Pharma Inc. | $94.05 | 5 |
| AbbVie Inc. | $71.01 | 4 |
| DEXCOM, INC. | $57.21 | 4 |
| Daiichi Sankyo Inc. | $39.24 | 2 |
| Biohaven Pharmaceuticals, Inc. | $37.69 | 2 |
| Amryt Pharma Holdings Ltd | $24.44 | 1 |
| Xeris Pharmaceuticals, Inc. | $20.69 | 1 |
| Novartis Pharmaceuticals Corporation | $16.41 | 1 |
| Eisai Inc. | $15.76 | 1 |
| Amgen Inc. | $14.53 | 1 |
| GlaxoSmithKline, LLC. | $12.20 | 1 |
Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HOWARD J RUBENSTEIN
NPI 1376598086 · CMS profile ID 244149
Allopathic & Osteopathic Physicians / Family Medicine
SARALAND, AL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1376598086?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HOWARD J RUBENSTEIN, NPI 1376598086, CMS profile ID 244149. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376598086?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). HOWARD J RUBENSTEIN, NPI 1376598086, CMS profile ID 244149. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376598086?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- HOWARD J RUBENSTEIN, NPI 1376598086, CMS profile ID 244149, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1376598086?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
61 matching records · $1,250.93 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 61.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $17.49 | 12/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819177249 | CMS |
| Lilly USA, LLC | $13.34 | 11/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819177261 | CMS |
| PFIZER INC. | $18.54 | 11/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833174777 | CMS |
| PFIZER INC. | $11.54 | 11/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833444879 | CMS |
| AbbVie Inc. | $29.07 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795897381 | CMS |
| Amarin Pharma Inc. | $16.39 | 10/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815043161 | CMS |
| Lilly USA, LLC | $12.81 | 10/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819189819 | CMS |
| DEXCOM, INC. | $13.33 | 10/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845296217 | CMS |
| Novo Nordisk Inc | $1.28 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811269921 | CMS |
| Novo Nordisk Inc | $13.79 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811675161 | CMS |
| Merck Sharp & Dohme Corporation | $16.28 | 10/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848647473 | CMS |
| Novartis Pharmaceuticals Corporation | $16.41 | 09/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813215411 | CMS |
| Lilly USA, LLC | $15.25 | 09/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819189815 | CMS |
| AbbVie Inc. | $14.25 | 09/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795897377 | CMS |
| Amarin Pharma Inc. | $18.58 | 09/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815160577 | CMS |
| PFIZER INC. | $16.92 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833396905 | CMS |
| Amgen Inc. | $14.53 | 09/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825357611 | CMS |
| DEXCOM, INC. | $12.06 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845296215 | CMS |
| Lilly USA, LLC | $18.29 | 08/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819087061 | CMS |
| PFIZER INC. | $18.59 | 08/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832832231 | CMS |
| Novo Nordisk Inc | $16.59 | 08/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811561753 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830096241 | CMS |
| Merck Sharp & Dohme Corporation | $17.97 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848516349 | CMS |
| Xeris Pharmaceuticals, Inc. | $20.69 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837443091 | CMS |
| Biohaven Pharmaceuticals, Inc. | $22.08 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852606927 | CMS |
| Lilly USA, LLC | $11.64 | 07/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818565285 | CMS |
| Amarin Pharma Inc. | $18.58 | 07/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815160573 | CMS |
| PFIZER INC. | $15.06 | 07/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833473587 | CMS |
| DEXCOM, INC. | $17.65 | 06/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845296213 | CMS |
| Esperion Therapeutics, Inc. | $125.00 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838390815 | CMS |
| Daiichi Sankyo Inc. | $20.89 | 06/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836298767 | CMS |
| AbbVie Inc. | $12.95 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795897373 | CMS |
| Merck Sharp & Dohme Corporation | $19.77 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848724209 | CMS |
| Novo Nordisk Inc | $16.42 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811415167 | CMS |
| Novo Nordisk Inc | $64.80 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811415161 | CMS |
| Novo Nordisk Inc | $19.22 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811561747 | CMS |
| PFIZER INC. | $11.68 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833560419 | CMS |
| Amryt Pharma Holdings Ltd | $24.44 | 05/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832287313 | CMS |
| DEXCOM, INC. | $14.17 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845296211 | CMS |
| Amarin Pharma Inc. | $19.44 | 04/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815160579 | CMS |
| Novo Nordisk Inc | $19.64 | 04/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810627715 | CMS |
| PFIZER INC. | $11.72 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832740919 | CMS |
| Lilly USA, LLC | $16.51 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819177245 | CMS |
| PFIZER INC. | $13.96 | 04/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833420855 | CMS |
| Lilly USA, LLC | $16.79 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819190317 | CMS |
| Merck Sharp & Dohme Corporation | $15.37 | 04/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848399135 | CMS |
| GlaxoSmithKline, LLC. | $12.20 | 04/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803144635 | CMS |
| PFIZER INC. | $17.99 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833575049 | CMS |
| Merck Sharp & Dohme Corporation | $13.45 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848488077 | CMS |
| Lilly USA, LLC | $13.84 | 03/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819177257 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $290,410.38 | 20 |
| PY2024 | Principal investigator | $582,175.45 | 67 |
| PY2023 | Principal investigator | $178,596.47 | 28 |
| PY2022 | Principal investigator | $323,131.01 | 30 |
| PY2021 | Principal investigator | $410,276.56 | 30 |
| PY2020 | Recipient | $1,694.65 | 7 |
| PY2020 | Principal investigator | $897,181.33 | 26 |
| PY2019 | Principal investigator | $623,481.03 | 21 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
21 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | CIPLA USA INC. | $300.00 | 11/27/2019 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | U-FS-MU-AS3120 | No dispute reported | 06/30/2026 | 694712619 |
| Principal investigator 1 | CIPLA USA INC. | $7,127.90 | 11/12/2019 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | U-FS-MU-AS3120 | No dispute reported | 06/30/2026 | 694712707 |
| Principal investigator 1 | CIPLA USA INC. | $3,950.00 | 11/12/2019 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | U-FS-MU-AS3120 | No dispute reported | 06/30/2026 | 694712709 |
| Principal investigator 1 | CIPLA USA INC. | $3,007.22 | 10/31/2019 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | U-FS-MU-AS3120 | No dispute reported | 06/30/2026 | 694717047 |
| Principal investigator 1 | CIPLA USA INC. | $20.00 | 10/01/2019 | Non-covered Recipient Entity THE CENTER FOR CLINICAL TRIALS - RESEARCH | U-FS-MU-AS3120 | No dispute reported | 06/30/2026 | 694710301 |
| Principal investigator 1 | CIPLA USA INC. | $24.00 | 10/01/2019 | Non-covered Recipient Entity THE CENTER FOR CLINICAL TRIALS - RESEARCH | U-FS-MU-AS3120 | No dispute reported | 06/30/2026 | 694712729 |
| Principal investigator 1 | PFIZER INC. | $158,610.84 | 10/01/2019 | Non-covered Recipient Entity THE CENTER FOR CLINICAL TRIALS | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN | No dispute reported | 06/30/2026 | 671665745 |
| Principal investigator 1 | CIPLA USA INC. | $7,200.67 | 07/25/2019 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | U-FS-MU-AS3120 | No dispute reported | 06/30/2026 | 694711813 |
| Principal investigator 1 | CIPLA USA INC. | $16.80 | 07/23/2019 | Non-covered Recipient Entity THE CENTER FOR CLINICAL TRIALS - RESEARCH | U-FS-MU-AS3120 | No dispute reported | 06/30/2026 | 694714843 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.44 | 07/11/2019 | Non-covered Recipient Entity THE CTR FOR CLINICAL TRIALS INC | Exercise capacity study in HFpEF | No dispute reported | 06/30/2026 | 704143379 |
| Principal investigator 1 | CIPLA USA INC. | $160.55 | 06/18/2019 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | U-FS-MU-AS3120 | No dispute reported | 06/30/2026 | 694718023 |
| Principal investigator 1 | PFIZER INC. | $7,075.00 | 06/17/2019 | Non-covered Recipient Entity THE CENTER FOR CLINICAL TRIALS | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN | No dispute reported | 06/30/2026 | 671622799 |
| Principal investigator 1 | PFIZER INC. | $25,116.83 | 06/03/2019 | Non-covered Recipient Entity THE CENTER FOR CLINICAL TRIALS | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN | No dispute reported | 06/30/2026 | 671622783 |
| Principal investigator 1 | AstraZeneca UK Limited | $3,997.00 | 05/20/2019 | Non-covered Recipient Entity Elias Research Associates Llc | A 26 Week Multicenter Randomized Placebo Controlled Double Blind Parallel Group Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 years of age | No dispute reported | 06/30/2026 | 685000063 |
| Principal investigator 1 | PFIZER INC. | $7,100.00 | 04/30/2019 | Non-covered Recipient Entity THE CENTER FOR CLINICAL TRIALS | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN | No dispute reported | 06/30/2026 | 671622797 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $283,588.06 | 04/10/2019 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | No dispute reported | 06/30/2026 | 696053981 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $68,936.35 | 04/10/2019 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 696053995 |
| Principal investigator 1 | PFIZER INC. | $48.00 | 02/01/2019 | Non-covered Recipient Entity THE CENTER FOR CLINICAL TRIALS | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN | No dispute reported | 06/30/2026 | 671637795 |
| Principal investigator 1 | PFIZER INC. | $2,395.90 | 01/03/2019 | Non-covered Recipient Entity THE CENTER FOR CLINICAL TRIALS | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN | No dispute reported | 06/30/2026 | 671695415 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $44,730.47 | 01/02/2019 | Non-covered Recipient Entity Elias Research Associates LLC | Exercise capacity study in HFrEF | No dispute reported | 06/30/2026 | 704143421 |
| Principal investigator 1 | PFIZER INC. | $48.00 | 01/01/2019 | Non-covered Recipient Entity THE CENTER FOR CLINICAL TRIALS | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN | No dispute reported | 06/30/2026 | 671637793 |